Skip to content

Usability and Feasibility of a Personalized, Web-based Education and Self-management Approach for Patients With Chronic Heart Failure Across Four European Sites

Usability and Feasibility of a Personalized, Web-based Education and Self-management Approach for Patients With Chronic Heart Failure Across Four European Sites

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04699253
Acronym
STABILISE-HF
Enrollment
542
Registered
2021-01-07
Start date
2021-07-01
Completion date
2023-12-31
Last updated
2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Keywords

chronic heart failure, patient self-management, patient education, web application

Brief summary

The STABELISE-HF is an investigator initiated, international, multicentre feasibility study that will investigate the use of a web application called SanaCoach Heart failure in patients with chronic heart failure. SanaCoach heart failure provides patient education, systematic self-monitoring, a care plan repository and facilitates correspondence with patient's care provider.

Detailed description

Patients with chronic heart failure are encouraged to self-manage their illness, such as adhering to medical regimens, monitoring symptoms and adhere to lifestyle recommendations from the health care provider to optimise health outcomes and quality of life. Consented study participants meeting the eligibility criteria for the STABILISE HF study will be using the the SanaCoach heart failure during a 6-month study period. SanaCoach heart failure is an application on the internet that supports patients and care providers in the development, implementation and monitoring of patient self-management. The SanaCoach heart failure provides information about heart failure, treatment, and lifestyle modifications. It can also monitor the patient's wellbeing, symptoms, vital signs, and gives advice on whether review with a health care provider is advisable. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder. Recruitment and dropout statistics will be assessed and the sociodemographic and comorbidity profile of consenting study participants as well as consenting non-participants (Patients who decide not to participate will be given an option to complete an anonymous sociodemographic survey.) will be analysed.

Interventions

DEVICESanaCoach Heart failure

Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.

Sponsors

RWTH Aachen University
CollaboratorOTHER
Queen's University, Belfast
CollaboratorOTHER
University College Dublin
CollaboratorOTHER
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must meet ALL of the following criteria in order to be eligible for this study. * Adults (≥18 years) that own a device where SanaCoach heart failure can be used on * Diagnosis of chronic heart failure according to ESC 2016 guidelines (HFrEF = LVEF \<40%, HFmrEF = LVEF 40-49%, HFpEF = LVEF ≥ 50%), based on echocardiographic or MRI findings within the last year or considered stable before. * Ability and willingness to give written informed consent and to comply with the requirements of the study

Exclusion criteria

Patients meeting any of the following criteria are NOT eligible for this study * Patients without access to a device where SanaCoach heart failure can be used on * Uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk (according to investigator's \[or delegate\] judgment) if he/she participates in the clinical study. * Patients that have been hospitalised for heart failure within the last 30 days. * An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results. * Treatment with other investigational products or devices within 30 days or five half-lives of the screening visit, whichever is longer. * Planned use of other investigational products or devices during the course of the study. * Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to: * a. Subjects who are unable to communicate or to cooperate with the investigator. * b. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study. * c. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study). * d. Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study * e. Persons directly involved in the conduct of the study.

Design outcomes

Primary

MeasureTime frameDescription
Usability of the SanaCoach heart failureBaseline to 6 months• Score on the System Usability Scale (SUS)

Secondary

MeasureTime frameDescription
UsabilityBaseline to 6 months* % of users who rate SanaCoach heart failure as easy to use * % of users who rate SanaCoach heart failure as transmits information as intended * % of users who report satisfaction with the content of information received via SanaCoach heart failure * % of users motivated/intending to use SanaCoach heart failure * % of alerts/messages transmitted via the app that are rated appropriate by patient * % of alerts/messages transmitted via the app that are responded to appropriately by patient
Feasibility of the SanaCoach heart failureBaseline to 6 months* Total number of hours of initial training on the use of SanaCoach heart failure attended by staff, patients, cardiologist * Total number of hours of refresher training on the use of SanaCoach heart failure attended by staff, patients, cardiologists * Total number of minutes/hours for patient counselling over study duration * Total number of minutes/hours spent on health record-keeping over study duration
AcceptabilityBaseline to 6 months• Rate of completion of the intervention (i.e. number of participants who access and complete all aspects of the intervention including lifestyle coach support
Adherence ratesBaseline to 6 months• Number of completed/uncompleted education and monitoring sessions
Technology readiness index (TRI)Baseline to 6 monthsTechnology readiness index (TRI)

Other

MeasureTime frameDescription
Well-Being IndexBaseline to 6 months• World Health Organisation- Five Well-Being Index (WHO-5) from baseline to weeks 12 and 26.
Medication adherenceBaseline to 6 months• Changes in self-reported Medication adherence using the Medication Adherence Report Scale (MARS) from baseline to week 26.
Quality of life assessmentBaseline to 6 months• Changes in the Quality of life assessment with Kansas City Cardiomyopathy Questionnaire (KCCQ-12) from baseline to weeks 12 and 26.
Self-care BehaviourBaseline to 6 months• Changes on the 9-Item European Heart Failure Self-care Behaviour Scale (EHFScB-9) from baseline to week 26.
EffectivenessBaseline to 6 months* Number of unscheduled visits due to HF during the study period. * Number of cardiac rehospitalisation during the study period

Countries

Germany, Ireland, Netherlands, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026